Tim Rahmel

Dr. Tim Rahmel

Anesthesiology, Intensive Care and Pain Therapy, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, North Rhine-Westphalia, Germany
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Tim RahmelTim Rahmel
Tim Rahmel
SSStefanie Schmitz
Stefanie Schmitz
HNHartmuth Nowak
Hartmuth Nowak
KSKaspar Schepanek
Kaspar Schepanek
LBLars Bergmann
Lars Bergmann
MAMichael Adamzik
Michael Adamzik
Patients with severe infections and especially sepsis have a high in-hospital mortality, but even hospital survivors face long-term sequelae, decreased health-related quality of life, and high risk of death, suggesting a great need for specialized aftercare. However, data regarding a potential benefit of post-discharge rehabilitation in these patients are scarce. In this retrospective matched cohort study the claim data of a large German statutory health care insurer was analyzed. 83,974 hospital survivors having suffered from septic shock, sepsis, and severe infections within the years 2009–2016 were identified using an ICD abstraction strategy closely matched to the current Sepsis-3 definition. Cases were analyzed and compared with their matched pairs to determine their 5-year mortality and the impact of post-discharge rehabilitation. Five years after hospital discharge, mortality of initial hospital survivors were still increased after septic shock (HRadj 2.03, 95%-CI 1.87 to 2.19; P<0.001), sepsis (HRadj 1.73, 95%-CI 1.71 to 1.76; P<0.001), and also in survivors of severe infections without organ dysfunction (HRadj 1.70, 95%-CI 1.65 to 1.74; P<0.001) compared to matched controls without infectious diseases. Strikingly, patients treated in rehabilitation facilities showed a significantly improved 5-year survival after suffering from sepsis or septic shock (HRadj 0.81, 95%-CI 0.77 to 0.85; P<0.001) as well as severe infections without organ dysfunction (HRadj 0.81, 95%-CI 0.73 to 0.90; P<0.001) compared to matched patients discharged to home or self-care. Long-term mortality and morbidity of hospital survivors are markedly increased after septic shock, sepsis and severe infections without organ dysfunction, but best 5-year survival was recorded in patients discharged to a rehabilitation facility in all three groups. Thus, our data suggest that specialized aftercare programs may help to improve long-term outcome in these patients and warrants more vigilance in future investigations.

13 July 2018 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
JMJohanna Müssig
Johanna Müssig
ANAmir M. Nia
Amir M. Nia
MMMaryna Masyuk
Maryna Masyuk
ALAlexander Lauten
Alexander Lauten
ASAnne Lena Sacher
Anne Lena Sacher
CJChristian Jung
Christian Jung
In intensive care units (ICU) octogenarians become a routine patients group with aggravated therapeutic and diagnostic decision-making. Due to increased mortality and a reduced quality of life in this high-risk population, medical decision-making a fortiori requires an optimum of risk stratification. Recently, the VIP-1 trial prospectively observed that the clinical frailty scale (CFS) performed well in ICU patients in overall-survival and short-term outcome prediction. However, it is known that healthcare systems differ in the 21 countries contributing to the VIP-1 trial. Hence, our main focus was to investigate whether the CFS is usable for risk stratification in octogenarians admitted to diversified and high tech German ICUs. This multicentre prospective cohort study analyses very old patients admitted to 20 German ICUs as a sub-analysis of the VIP-1 trial. Three hundred and eight patients of 80 years of age or older admitted consecutively to participating ICUs. CFS, cause of admission, APACHE II, SAPS II and SOFA scores, use of ICU resources and ICU- and 30-day mortality were recorded. Multivariate logistic regression analysis was used to identify factors associated with 30-day mortality. Patients had a median age of 84 [IQR 82–87] years and a mean CFS of 4.75 (± 1.6 standard-deviation) points. More than half of the patients (53.6%) were classified as frail (CFS ≥ 5). ICU-mortality was 17.3% and 30-day mortality was 31.2%. The cause of admission (planned vs. unplanned), (OR 5.74) and the CFS (OR 1.44 per point increase) were independent predictors of 30-day survival. The CFS is an easy determinable valuable tool for prediction of 30-day ICU survival in octogenarians, thus, it may facilitate decision-making for intensive care givers in Germany. The VIP-1 study was retrospectively registered on ClinicalTrials.gov (ID: NCT03134807 ) on May 1, 2017.

3 December 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Tim RahmelTim Rahmel
Tim Rahmel
BMBritta Marko
Britta Marko
HNHartmuth Nowak
Hartmuth Nowak
LBLars Bergmann
Lars Bergmann
PTPatrick Thon
Patrick Thon
BKBjörn Koos
Björn Koos
Sepsis is characterized by a dysregulated immune response, metabolic derangements and bioenergetic failure. These alterations are closely associated with a profound and persisting mitochondrial dysfunction. This however occurs despite increased expression of the nuclear-encoded transcription factor A (TFAM) that normally supports mitochondrial biogenesis and functional recovery. Since this paradox may relate to an altered intracellular distribution of TFAM in sepsis, we tested the hypothesis that enhanced extramitochondrial TFAM expression does not translate into increased intramitochondrial TFAM abundance. Accordingly, we prospectively analyzed PBMCs both from septic patients (n = 10) and lipopolysaccharide stimulated PBMCs from healthy volunteers (n = 20). Extramitochondrial TFAM protein expression in sepsis patients was 1.8-fold greater compared to controls (p = 0.001), whereas intramitochondrial TFAM abundance was approximate 80% less (p < 0.001). This was accompanied by lower mitochondrial DNA copy numbers (p < 0.001), mtND1 expression (p < 0.001) and cellular ATP content (p < 0.001) in sepsis patients. These findings were mirrored in lipopolysaccharide stimulated PBMCs taken from healthy volunteers. Furthermore, TFAM-TFB2M protein interaction within the human mitochondrial core transcription initiation complex, was 74% lower in septic patients (p < 0.001). In conclusion, our findings, which demonstrate a diminished mitochondrial TFAM abundance in sepsis and endotoxemia, may help to explain the paradox of lacking bioenergetic recovery despite enhanced TFAM expression.

10 July 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
Tim RahmelTim Rahmel
Tim Rahmel
DEDavid Effinger
David Effinger
TBThilo Bracht
Thilo Bracht
LGLeonore Griep
Leonore Griep
BKBjörn Koos
Björn Koos
SKSimone Kreth
Simone Kreth
Patients with sepsis experience metabolic and immunologic dysfunction that may be amplified by standard carbohydrate-based nutrition. A ketogenic diet (KD) may offer an immunologically advantageous alternative, although clinical evidence is limited. We conducted a single-center, open-label, randomized controlled trial to assess whether a KD could induce stable ketosis in critically ill patients with sepsis. Secondary outcomes included assessment of feasibility and safety of KD, as well as explorative analysis of clinical and immunological characteristics. Forty critically ill adults were randomized to either a ketogenic or standard high-carbohydrate diet. Stable ketosis was achieved in all KD patients, with significant increases in β-hydroxybutyrate levels compared with controls [mean difference 1.4 milimoles per liter; 95% confidence interval (CI): 1.0 to 1.8; P < 0.001). No major adverse events or harmful metabolic side effects (acidosis, dysglycemia, or dyslipidemia) were observed. After day 4, none of the patients in the KD group required insulin treatment, whereas in the control group, insulin dependency ranged between 35% and 60% ( P = 0.009). There were no differences in 30-day survival, but ventilation-free [incidence rate ratio (IRR) 1.7; 95% CI: 1.5 to 2.1; P < 0.001], vasopressor-free (IRR 1.7; 95% CI: 1.5 to 2.0; P < 0.001), dialysis-free (IRR 1.5; 95% CI: 1.3 to 1.8; P < 0.001), and intensive care unit–free days (IRR 1.7; 95% CI: 1.4 to 2.1; P < 0.001) were higher in the ketogenic group. Next-generation sequencing of CD4 + /CD8 + T cells and protein analyses showed reduced immune dysregulation, with decreased gene expression of T-cell activation and signaling markers and lower pro-inflammatory cytokine secretion. This trial demonstrated the safe induction of a stable ketogenic state in sepsis, warranting larger trials to investigate potential benefits in sepsis-related organ dysfunction.

21 May 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Tim RahmelTim Rahmel
Tim Rahmel
SSSimon Thomas Schäfer
Simon Thomas Schäfer
Ulrich FreyUlrich Frey
Ulrich Frey
MAMichael Adamzik
Michael Adamzik
JPJürgen Peters
Jürgen Peters
Sepsis is now operationally defined as life-threatening organ dysfunction caused by an infection, identified by an acute change in SOFA-Score of at least two points, including clinical chemistry such as creatinine or bilirubin concentrations. However, little knowledge exists about organ-specific microRNAs as potentially new biomarkers. Accordingly, we tested the hypotheses that micro-RNA-122, the foremost liver-related micro-RNA (miR), 1) discriminates between sepsis and infection, 2) is an early predictor for mortality, and 3) improves the prognostic value of the SOFA-score. We analyzed 108 patients with sepsis (infection + increase SOFA-Score ≥2) within the first 24h of ICU admission and as controls 20 patients with infections without sepsis (infection + SOFA-Score ≤1). Total circulating miR was isolated from serum and relative miR-122 expression was measured (using spiked-in cel-miR-54) and associated with 30-day survival. 30-day survival of the sepsis patients was 63%. miR-122 expression was 40-fold higher in non-survivors (p = 0.001) and increased almost 6-fold in survivors (p = 0.013) compared to controls. miR-122 serum-expression discriminated both between sepsis vs. infection (AUC 0.760, sensitivity 58.3%, specificity 95%) and survivors vs. non-survivors (AUC 0.728, sensitivity 42.5%, specificity 94%). Multivariate Cox-regression analysis revealed miR-122 (HR 4.3; 95%-CI 2.0–8.9, p<0.001) as independent prognostic factor for 30-day mortality. Furthermore, the predictive value for 30-day mortality of the SOFA-Score (AUC 0.668) was improved by adding miR-122 (AUC 0.743; net reclassification improvement 0.37, p<0.001; integrated discrimination improvement 0.07, p = 0.007). Increased miR-122 serum concentration supports the discrimination between infection and sepsis, is an early and independent risk factor for 30-day mortality, and improves the prognostic value of the SOFA-Score, suggesting a potential role for miR-122 in sepsis-related prediction models.

18 August 2025 in Medizinische Klinik - Intensivmedizin und Notfallmedizin
Verified
Journal Article
Open access
PDF file
FBFrank M. Brunkhorst
Frank M. Brunkhorst
MAMichael Adamzik
Michael Adamzik
Hubertus AxerHubertus Axer
Hubertus Axer
Michael BauerMichael Bauer
Michael Bauer
CBChristian Bode
Christian Bode
Alexander ZarbockAlexander Zarbock
Alexander Zarbock
Zusammenfassung: Hintergrund: Sepsis ist eine akut lebensbedrohliche multiple Organdysfunktion, ausgelöst durch eine Infektion. Methodik: Bei der vorliegenden Leitlinie handelt es sich um ein Update der S3-Leitlinie „Sepsis – Prävention, Diagnose, Therapie und Nachsorge“ (AMWF-Register-Nr.: 079–001) der Deutschen Sepsis-Gesellschaft (DSG) vom 31.12.2018. Dabei wurde das Update der „Surviving sepsis campaign (SSC): international guidelines for management of sepsis and septic shock 2021“ vom 04.10.2021 als Referenzleitlinie zugrunde gelegt. Die DSG-Leitlinienkommission verglich jede Empfehlung zu den zugrunde liegenden PICO-Fragen der DSG-Leitlinie 2018 (Literaturrecherche bis 12/2018) mit denen der SSC-Leitlinie 2021 (Literaturrecherche bis 07/2019) und bewertete die in der Zwischenzeit neu verfügbare publizierte Datenlage (Literaturrecherche bis 12/2024) mittels systematischer Aktualisierungsrecherchen und Literaturbewertungen unter Befolgung des Regelwerkes des GRADE-Systems und der AWMF. Ergebnisse: Insgesamt wurden 88 PICO-Fragen u. a. zur Diagnose und Therapie der Infektion und des Organversagens adressiert. Davon wurden 2 als Statements, 29 als Expertenkonsens und 57 als evidenzbasierte Empfehlungen (26 mit starkem und 31 mit schwachem Empfehlungsgrad) konsentiert. Im Vergleich zur Vorgänger-Leitlinie 2018 wurden 43 Empfehlungen überprüft, aber beibehalten. 16 Empfehlungen wurden geändert, und 29 Empfehlungen wurden neu ausgesprochen. Schlussfolgerung: Angesichts fehlender Evidenz für zahlreiche Maßnahmen zur stationären Versorgung von Patienten mit Sepsis oder septischem Schock wurden alte und neue Wissenslücken offenbart. Bei den evidenzbasierten Empfehlungen war die zugrunde liegende Evidenzqualität nach GRADE nur bei 5 Empfehlungen hoch, bei 18 Empfehlungen moderat, bei 17 Empfehlungen niedrig und bei 16 sehr niedrig. Diese Evidenzlücken können nur durch zukünftige multizentrische, nichtkommerzielle klinische Prüfungen geschlossen werden. Das Update der S3-Leitlinie Sepsis beinhaltet einige Aktualisierungen zu Empfehlungen der Vorgängerleitlinie. Diese Aktualisierungen werden in einige der fall- und einrichtungsbezogenen QS-Indikatoren des QS-Verfahrens 2025 einfließen müssen. Beeinträchtigungen in der gesundheitsbezogenen Lebensqualität müssen bei Überlebenden mehr in den Fokus der ambulanten Versorgung gerückt werden.